Secondary analysis of NORD-STAR (795 patients, early rheumatoid arthritis): all arms improved patient-reported outcomes at 48 weeks; certolizumab pegol, abatacept or tocilizumab vs active conventional therapy gave somewhat larger pain and fatigue gains; differences were small.
Secondary analysisn = 812
Lampa et al. Certolizumab pegol, abatacept, tocilizumab or active conventional therapy in early rheumatoid arthritis: 48-week patient-reported outcomes from the NORD-STAR trial